Jump to content
Sclero Forums

Search the Community

Showing results for tags 'lupus complications'.



More search options

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • Worldwide
    • Welcome: Guidelines and FAQs
    • Sclero Forums (MAIN)
    • UK Scleroderma
    • News
    • Personal Support

Blogs

  • CFM Babs from Chorley FM
  • barefut impressions
  • My Two Cents...
  • Amanda Thorpe's Blog
  • Joelf's Blog
  • Michael Thorpe's Blog

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Joined

  • Start

    End


Group


Location

Found 16 results

  1. Interleukin-34 as a marker for subclinical proliferative lupus nephritis (LN). Serum IL-34 may be used as a surrogate marker for early renal affection in silent LN, especially the proliferative type. Sage Journals, Lupus, 04/01/2020. (Also see Symptoms and Complications of Lupus and Interleukins) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  2. Retinal Complications in Patients with Systemic Lupus Erythematosus Treated with Antimalarial Drugs. Just over 5% of patients developed antimalarial retinal complications, over an average of 12.8 years, but no cases were detected in the first 5 years of therapy. PubMed, J Rheumatol, 2020 Apr;47(4):553-556. (Also see Symptoms and Complications of Lupus and DMARDs) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  3. Profiling of non-criteria antiphospholipid antibodies in patients with systemic lupus erythematosus (SLE): differentiation of thrombotic SLE patients and risk of recurrence of thrombosis. Profiling of antiphospholipid antibodies by line immunoassay can differentiate SLE patients with thrombosis from SLE patients without thrombosis. PubMed, Lupus, 2020 Mar 4:961203320909952. (Also see Antibodies in Lupus and Symptoms and Complications of Lupus) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  4. Construction of a Frailty Index (FI) as a Novel Health Measure in Systemic Lupus Erythematosus (SLE). The SLICC-FI may be a useful tool for identifying patients with SLE who are most vulnerable to adverse outcomes. PubMed, J Rheumatol, 2020 Jan;47(1):72-81. (Also see Symptoms and Complications of Lupus) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  5. Systemic lupus erythematosus (SLE) is a risk factor for atrial fibrillation (AF): a nationwide, population-based study. Development of AF in patients with SLE was associated with increased mortality. PubMed, Clin Exp Rheumatol, 2019 Nov-Dec;37(6):1019-1025. (Also see Symptoms and Complications of Lupus) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  6. The Impact of Systemic Lupus Erythematosus (SLE) on the Risk of Newly Diagnosed Hip Fracture. A General Population-Based Study. Patients with newly diagnosed SLE have a 62% increased risk of hip fractures compared to non-SLE individuals. PubMed, Arthritis Care Res (Hoboken), 11/23/2019. (Also see Symptoms and Complications of Lupus) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  7. Different patterns of cerebral perfusion in systemic lupus erythematosus (SLE) patients with and without neuropsychiatric (NP) manifestations. Cerebral blood flow measured by noninvasive three-dimensional arterial spin labeling could be a useful biomarker for the diagnosis and disease monitoring of NPSLE and non-NPSLE patients. PubMed, Hum Brain Mapp, 10/24/2019. (Also see Symptoms and Complications of Lupus) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  8. Biomarkers associating endothelial Dysregulation in pediatric-onset systemic lupus erythematous (pSLE). Endothelial dysregulation associating proteins seems to be potent biomarkers for pSLE activity as well as organ involvement in pSLE patients. PubMed, Pediatr Rheumatol Online J, 2019 Oct 24;17(1):69. (Also see Symptoms and Complications of Lupus) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  9. Dysregulated Fc gamma receptor IIa-induced cytokine production in dendritic cells (DCs) of lupus nephritis patients. We identified that DCs of lupus nephritis patients show increased Fcγ R-induced IL-1β production, which is another important cytokine that promotes kidney inflammation. PubMed, Clin Exp Immunol, 09/11/2019. (Also see Symptoms and Complications of Lupus) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  10. Heart failure (HF) risk in systemic lupus erythematosus (SLE) compared to diabetes mellitus (DM) and general medicaid patients. Further investigation into the biologic mechanism of HF among SLE compared to non-SLE and DM patients may shed light on the findings of this study. PubMed, Semin Arthritis rheumatologist, 06/11/2019. (Also see Symptoms and Complications of Lupus and Symptoms and Complications of Diabetes) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  11. Complement alternative pathway activation associated with pulmonary hypertension in lupus nephritis patients. Activation of the complement alternative pathway may be involved in the pathogenesis of pulmonary hypertension in lupus nephritis. PubMed, Lupus, 2019 Jul 11:961203319860192. (Also see Symptoms and Complications of Lupus and Pulmonary Hypertension) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  12. Septic shock among patients with systemic lupus erythematosus (SLE): short and long–term outcome. Analysis of a French nationwide database. Septic shock is a frequent and severe complication among SLE patients even if it is not associated with more healthcare use than another episode of same severity. PubMed, J Infect, 04/08/2019. (Also see Symptoms and Complications of Lupus) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles. 
  13. Metabolic syndrome (MetS) in patients with systemic lupus erythematosus: Association with disease activity, disease damage and age. The frequency of MetS was not significantly different from that of the control group, but almost half of the patients were found with this syndrome. PubMed, Int J rheumatologist Dis, 04/03/2018. (Also see Symptoms and Complications of Lupus) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  14. Endothelial dysfunction in early systemic lupus erythematosus patients and controls without previous cardiovascular events. A high rate of endothelial dysfunction and vascular stiffness occurs in early lupus patients without cardiovascular risk factors and disease. PubMed, Arthritis Care Res (Hoboken), 12/15/2017. (Also see Symptoms and Complications of Lupus) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  15. Cerebrovascular Events (CerVEs) in Systemic Lupus Erythematosus (SLE). CerVEs, the fourth most frequent neuropsychiatric event in SLE, are usually attributable to lupus. PubMed, Arthritis Care Res (Hoboken), 01/05/2018. (Also see Symptoms and Complications of Lupus) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  16. A retrospective study of joint infections in patients with systemic lupus erythematosus (SLE). When an SLE patient presents with pre–existing arthritis and suddenly develops asymmetric oligo– or large–joint swelling and pain with elevated C-reactive protein levels and low disease activity, joint infections should be considered. PubMed, Clin Rheumatol, 07/08/2017. (Also see Symptoms and Complications of Lupus) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
×
×
  • Create New...